Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
991 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02835599 | Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now(REVOLUTION) | terminated | — | 23 | AstraZenecaINDUSTRY | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02300831 | LUMINIST: LUng Cancer Molecular Insights Non Interventional Study(LUMINIST) | completed | — | 770 | AstraZenecaINDUSTRY | 23 | Jul 14, 2017 |
| clinicaltrials |
| NCT01957579 | A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00338182 | AZD1152 in Patients With Advanced Solid Malignancies | completed | Phase 1 | 43 | AstraZenecaINDUSTRY | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT02087241 | Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | terminated | Phase 2 | 22 | AstraZenecaINDUSTRY | 1 | Mar 29, 2017 | clinicaltrials |
| NCT02475720 | Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC) | completed | — | 2,000 | AstraZenecaINDUSTRY | 1 | Mar 27, 2017 | clinicaltrials |
| NCT01457846 | Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer(SHINE) | terminated | Phase 2 | 960 | AstraZenecaINDUSTRY | 16 | Mar 7, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT02262273 | OSCA - Olaparib Standard of CAre Study(OSCA) | completed | — | 2,123 | AstraZenecaINDUSTRY | 13 | Mar 1, 2017 | clinicaltrials |
| NCT01395524 | A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation | completed | Phase 3 | 302 | AstraZenecaINDUSTRY | 4 | Feb 23, 2017 | clinicaltrials |
| NCT00423332 | Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma | completed | Phase 2 | 105 | AstraZenecaINDUSTRY | 2 | Feb 2, 2017 | clinicaltrials |
| NCT02153398 | A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases | completed | Phase 3 | 55 | AstraZenecaINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT01929603 | Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Jan 16, 2017 | clinicaltrials |
| NCT01974752 | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)(SUMIT) | completed | Phase 3 | 152 | AstraZenecaINDUSTRY | 11 | Jan 5, 2017 | clinicaltrials |
| NCT01203917 | Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC(IFUM) | completed | Phase 4 | 1,060 | AstraZenecaINDUSTRY | 13 | Jan 2, 2017 | clinicaltrials |
| NCT00399035 | Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer(HORIZON II) | completed | Phase 3 | 1,254 | AstraZenecaINDUSTRY | 15 | Dec 28, 2016 | clinicaltrials |
| NCT00777153 | Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma(REGAL) | completed | Phase 3 | 423 | AstraZenecaINDUSTRY | 10 | Dec 28, 2016 | clinicaltrials |
| NCT00912743 | Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status | completed | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Nov 9, 2016 | clinicaltrials |
| NCT01605916 | Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer | completed | Phase 1 | 33 | AstraZenecaINDUSTRY | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01894256 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 5 | Oct 13, 2016 | clinicaltrials |
| NCT02491944 | A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291 | completed | Phase 1 | 27 | AstraZenecaINDUSTRY | 1 | Oct 13, 2016 | clinicaltrials |
| NCT02260661 | Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours | completed | Phase 1 | 20 | AstraZenecaINDUSTRY | 2 | Oct 10, 2016 | clinicaltrials |
| NCT01947868 | Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor | completed | — | 346 | AstraZenecaINDUSTRY | 1 | Sep 23, 2016 | clinicaltrials |
| NCT02780830 | AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(INHIBITOR) | withdrawn | Phase 1 | 0 | AstraZenecaINDUSTRY | 0 | Sep 15, 2016 | clinicaltrials |
| NCT02322749 | A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers | completed | Phase 1 | 48 | AstraZenecaINDUSTRY | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00357734 | Iressa Follow-up Trial | completed | Phase 3 | 14 | AstraZenecaINDUSTRY | 1 | Aug 30, 2016 | clinicaltrials |
| NCT00454805 | AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. | completed | Phase 2 | 75 | AstraZenecaINDUSTRY | 3 | Aug 3, 2016 | clinicaltrials |
| NCT02063230 | To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Jul 21, 2016 | clinicaltrials |
| NCT02144051 | Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Jul 14, 2016 | clinicaltrials |
| NCT02451852 | AZD9291 US Expanded Access Program | no longer available | — | — | AstraZenecaINDUSTRY | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01448187 | Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa(EPIDAURE) | completed | — | 361 | AstraZenecaINDUSTRY | 1 | Jul 4, 2016 | clinicaltrials |
| NCT01213160 | Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient | completed | Phase 1 | 40 | AstraZenecaINDUSTRY | 1 | Jun 29, 2016 | clinicaltrials |
| NCT02224053 | Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers | completed | Phase 1 | 136 | AstraZenecaINDUSTRY | 1 | Jun 24, 2016 | clinicaltrials |
| NCT02087176 | A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer | terminated | Phase 2 | 48 | AstraZenecaINDUSTRY | 1 | Jun 14, 2016 | clinicaltrials |
| NCT00259064 | Iressa v BSC (Best Supportive Care) in First Line NSCLC(INSTEP) | completed | Phase 2 / Phase 3 | 216 | AstraZenecaINDUSTRY | 5 | Jun 2, 2016 | clinicaltrials |
| NCT01895946 | Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability(OAK) | completed | Phase 1 | 33 | AstraZenecaINDUSTRY | 2 | May 25, 2016 | clinicaltrials |
| NCT01562665 | Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf(Lung-EPICLIN/G) | completed | — | 25 | AstraZenecaINDUSTRY | 3 | May 24, 2016 | clinicaltrials |
| NCT01949870 | Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study | terminated | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | May 13, 2016 | clinicaltrials |
| NCT01501266 | Faslodex Specific Clinical Experience Investigation | completed | — | 660 | AstraZenecaINDUSTRY | 1 | May 10, 2016 | clinicaltrials |
| NCT01353781 | Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies | completed | Phase 1 | 39 | AstraZenecaINDUSTRY | 1 | Apr 26, 2016 | clinicaltrials |
| NCT02238782 | A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers. | completed | Phase 1 | 21 | AstraZenecaINDUSTRY | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01530334 | Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment(ICARUS) | completed | Phase 2 | 61 | AstraZenecaINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01026402 | Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 | completed | Phase 1 | 172 | AstraZenecaINDUSTRY | 1 | Feb 11, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT00554229 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases(ENTHUSE M1) | completed | Phase 3 | 896 | AstraZenecaINDUSTRY | 31 | Feb 8, 2016 | clinicaltrials |
| NCT00770588 | Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)(INFORM) | completed | Phase 4 | 296 | AstraZenecaINDUSTRY | 1 | Feb 8, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials